Últimas noticias sobre Renovaro (NASDAQ:RENB) Bolsa

Renovaro Biosciences

Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.

Renovaro Inc

renBTC

<a href="https://techcrunch.com/2025/06/26/rivian-cuts-dozens-on-manufacturing-team-ahead-of-r2-launch/">https://techcrunch.com/2025/06/26/rivian-cuts-dozens-on-manufacturing-team-ahead-of-r2-launch/</a>

News

General

RIVN

'Rivian cuts dozens on manufacturing team ahead of R2 launch'- Techcrunch

Susquehanna analyst Mehdi Hosseini maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Positive and raises the price target from $150 to $160.

Price Target

Analyst Ratings

Susquehanna Maintains Positive on Micron Technology, Raises Price Target to $160

Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) is reportedly navigating heightened union tensions as Workers United launches a bold initiative encouraging labor organizers<a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46053495/starbucks-green-apron-expansion-to-boost-service-but-squeeze-earnings-through-2027" rel="noreferrer noopener"> to apply for barista roles</a>.
The union&#8217;s move coincides with Starbucks&#8217; plans to bolster store staffing, potentially turning the company&#8217;s hiring spree into an unexpected organizing opportunity, Financial Times <a target="_blank" href="https://www.ft.com/content/89218b42-630e-4e8e-9720-b6b680c2022e" rel="noreferrer noopener">reports</a>.
Through a public campaign on social media, Workers United is recruiting &#8220;salts&#8221;—activists who seek employment with the aim of organizing from within.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/06/46066854/starbucks-denies-full-china-exit-amid-stake-sale-talks-as-market-share-slips-to-14" rel="noreferrer noopener">Starbucks Denies Full China Exit Amid Stake Sale Talks As Market Share Slips To 14%</a>
The initiative comes as the union has successfully won elections at 600 of Starbucks&#8217; more than 10,300 U.S. company-operated locations,
Starbucks executives recently acknowledged that prior staffing cuts weakened customer service. They subsequently announced a plan to expand headcount starting in August.
Last month, the union posted a call for applicants to join a new program that would assist them in landing jobs and organizing efforts from inside the cafés.
This open recruitment for salting reflects a strategic escalation and comes amid ongoing—but tense—contract negotiations with Starbucks. Walkouts over a new dress code last month underscored the strained relationship.
Starbucks criticized the union&#8217;s recruitment campaign, urging it to redirect energy toward finalizing a contract.
Sara Kelly, Starbucsk Chief Partner Officer, noted that more than 30 tentative agreements had been reached. She also warned against using resources to insert outside organizers, Financial Times adds.
Cornell labor expert Kate Bronfenbrenner explained that publicizing salting efforts signals sustained union pressure and intent to continue organizing efforts regardless of company resistance.
Meanwhile, Starbucks is denying reports it is considering a full exit from China. A spokesperson told Reuters the company isn't pursuing a full sale.
The Seattle-based company reportedly initiated a formal sale process in May, <a href="https://www.benzinga.com/markets/equities/25/06/46066854/starbucks-denies-full-china-exit-amid-stake-sale-talks-as-market-share-slips-to-14">with Goldman Sachs advising</a>.
Price Action: SBUX shares are trading lower by 0.48% to $90.62 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46117348/meta-secures-more-clean-energy-for-power-hungry-ai-and-data-center-growth" target="_blank" rel="noreferrer noopener">Meta Secures More Clean Energy For Power Hungry AI And Data Center Growth</a></li>
</ul>
Image: Shutterstock

Equities

Markets

Movers

SBUX

Union 'Salts' Stir The Pot As Starbucks Ramps Up Hiring

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is approaching a pivotal support zone that could define its trend for <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">the remainder of the cycle</a>.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
<td>Market Cap</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1598</td>
<td>&nbsp;$23.9 billion</td>
<td>-5.6%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001122</td>
<td>&nbsp;$6.6 billion</td>
<td>-2.4%&nbsp;</td>
</tr>
<tr>
<td>Pepe</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.059214</td>
<td>&nbsp;$3.9 billion</td>
<td>-10.3%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto analyst Kevin has <a href="https://x.com/Kev_Capital_TA/status/1938218851134489002">flagged</a> the $0.143–$0.127 range as the make-or-break level for Dogecoin. 
This zone aligns with a cluster of technical supports: the 200-week SMA/EMA, a long-term downtrend support line, and a historically key level on Dogecoin's weekly RSI.
Kevin notes that since DOGE broke out of its 1.5-year bear market in 2022, each revisit to this RSI support zone has marked a macro higher low, followed by higher highs. 
If this zone fails, it will break that structure and could mark the beginning of a longer-term bearish phase. 
If it holds, Kevin sees a strong risk-reward setup with upside continuation likely, especially if Bitcoin dominance remains high.
Trader Tardigrade drew comparisons to DOGE's previous cycle moves—$0.0003 to $0.0026 to $0.009—and suggests the current cycle could mirror that trajectory, potentially leading to jumps from $0.42 to $1.46 to $4.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> jumped from $0.0003 to $0.0026 to $0.009 in the last cycle &#x1f525; In this cycle, <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> could see similar jumps, from $0.42 to $1.46 to $4 &#x1f680;<a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a>/M1 <a href="https://t.co/k6kbCrqdVW">pic.twitter.com/k6kbCrqdVW</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1938236825728127080?ref_src=twsrc%5Etfw">June 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: Bitinfocharts shows a rise in wallet accumulation: wallets holding 10 million–100 million DOGE increased from 747 (as of May 25) to 783 (June 25) while wallets with 1 million–10 million DOGE rose from 4,204 to 4,228.
Coinglass data shows DOGE derivatives open interest increased 2.7% to $.8 billion, while volume expanded 11.2% to $3 billion. Liquidations in the past 24 hours stood at $4.09 million with long liquidations at $2.99 million.
Community News: Bitwise Asset Management has filed updated <a href="https://www.sec.gov/Archives/edgar/data/2053791/000121390025058120/ea0246815-s1a1_bitwise.htm">S-1</a> forms with the SEC, including a Bitwise Dogecoin ETF, a move that would provide exposure to DOGE without requiring direct token ownership.
Dogecoin core contributor Mishaboar <a href="https://x.com/mishaboar/status/1936838567445102769">voiced</a> criticism toward major influencers in the DOGE space. 
He claims many who previously amplified Elon Musk's pro-Trump messages have begun deleting posts and walking back their public stance. 
Mishaboar slammed this behaviour as cowardly, warning that such influence, even when retracted, has real impact.
"These influencers built their platforms on Dogecoin's back, and now they're using it to amplify misguided political and billionaire-driven narratives," he said.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46102135/bitcoin-ethereum-xrp-holders-sitting-on-profits-while-dogecoin-trails-report">Bitcoin, Ethereum, XRP Holders Sitting On Profits, While Dogecoin Trails: Report</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin ETF Nears But DOGE Down 5% In 7 Days: Bear Market Incoming?

Susquehanna analyst James Friedman maintains MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Positive and raises the price target from $2840 to $2975.

MELI

Susquehanna Maintains Positive on MercadoLibre, Raises Price Target to $2975

Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), a biotechnology company focused on developing treatments for rare muscle disorders, recently unveiled promising results from its <a href="https://www.benzinga.com/general/health-care">sevasemten program</a> for Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD). 
Both are progressive genetic disorders characterized by muscle weakness and degeneration, with DMD typically being more severe and having an earlier onset than BMD.
On Thursday, the company announced data from MESA. This open-label extension trial provides continued access to sevasemten to participants with Becker who were previously enrolled in ARCH or completed CANYON, GRAND CANYON, or DUNE.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44610702/edgewise-therapeutics-sees-meaningful-hcm-treatment-gains-with-edg-7500-in-phase-2-study" rel="noreferrer noopener">Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study</a>
As of the&nbsp;March 2025&nbsp;data cut, 99% of eligible participants (n=85) are enrolled in MESA. The MESA data demonstrated sustained disease stabilization.
CANYON participants who rolled over to MESA showed increased North Star Ambulatory Assessment (NSAA) scores over 18 months (0.8 point improvement from baseline), with a trend toward improvement in placebo participants switching to sevasemten (0.2 point improvement since <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46110778/edgewise-therapeutics-reports-positive-results-on-sevasemten-program-for-becker-and-duchenne-muscu" rel="noreferrer noopener">initiation of sevasemten)</a>.
NSAA measures functional motor abilities in ambulant (who can walk) children with Duchenne. During the 18 months of sevasemten treatment, participants&#8217; NSAA scores continued to diverge relative to the expected functional declines seen in multiple Becker natural history studies.
Further, NSAA scores for ARCH participants who rolled over to MESA remained stable after three years of treatment. Sevasemten demonstrates a favorable safety profile after up to three years of treatment.&nbsp;
Edgewise recently completed a Type C meeting with the U.S. Food and Drug Administration (FDA).
While the FDA deemed the CANYON data insufficient for accelerated approval, the Agency reiterated that NSAA is a clinically meaningful endpoint for traditional approval.
Accelerated approval is an FDA pathway that allows for earlier approval of drugs for serious conditions that fill an unmet medical need, based on a surrogate endpoint (a measure that is reasonably likely to predict clinical benefit). 
However, it requires confirmatory trials post-approval. Traditional approval, on the other hand, typically requires more extensive clinical trial data demonstrating direct clinical benefit.
GRAND CANYON is highly powered to show a statistically significant difference in NSAA versus placebo over 18 months and is on track for topline data in the fourth quarter of 2026.&nbsp;
The company also announced topline data from its Phase 2 Duchenne trials, LYNX and FOX.
The goals were to explore a range of doses to assess safety and identify a potentially beneficial dose for Phase 3. Across both studies, sevasemten was well-tolerated at target doses.
LYNX is an ongoing Phase 2 trial to evaluate the effect of sevasemten on safety, biomarkers of muscle damage, and function in four- to nine-year-old participants with Duchenne treated with sevasemten.
The company identified a dose of 10 mg to evaluate in Phase 3.&nbsp;
Similar to the LYNX design, FOX is an ongoing Phase 2 trial to evaluate the effect of sevasemten on safety, biomarkers of muscle damage, and function in six- to 14-year-old participants with Duchenne who have been previously treated with gene therapy.
The company plans to meet with the FDA in the fourth quarter of 2025 to discuss a Phase 3 design, including input on the patient population and endpoints, with plans to initiate the pivotal study in 2026.
Price Action: EWTX stock is down 11.6% at $12.68 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46117699/poet-technologies-stock-surges-on-ai-award-manufacturing-momentum" target="_blank" rel="noreferrer noopener">POET Technologies Stock Surges On AI Award, Manufacturing Momentum</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

EWTX

No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall

<a href="https://www.bloomberg.com/news/articles/2025-06-26/no-decision-imminent-on-next-fed-chair-white-house-says">https://www.bloomberg.com/news/articles/2025-06-26/no-decision-imminent-on-next-fed-chair-white-house-says</a>

'Trump Decision on Next Fed Chair Not Imminent, White House Says'- Bloomberg

Stifel analyst David Grossman maintains Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) with a Hold and lowers the price target from $156 to $152.

PAYX

Stifel Maintains Hold on Paychex, Lowers Price Target to $152

<a href="https://www.bloomberg.com/news/articles/2025-06-26/meta-in-talks-to-buy-ai-voice-startup-playai-in-push-for-talent" title="https://www.bloomberg.com/news/articles/2025-06-26/meta-in-talks-to-buy-ai-voice-startup-playai-in-push-for-talent">https://www.bloomberg.com/news/articles/2025-06-26/meta-in-talks-to-buy-ai-voice-startup-playai-in-push-for-talent</a>

'Meta in Talks to Buy AI Voice Startup PlayAI in Push for Talent' - Bloomberg News

<ul>
<li>Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service</li>
<li>Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorization of up to $500 million</li>
</ul>
QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025.
He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate Governance Code indicates that Directors of public companies should not serve more than 12 years for a company on their Supervisory Board.
At the AGM, where 80.4% of QIAGEN's issued shares were represented, shareholders approved all proposed resolutions, including the initiation of an annual cash dividend and a new share repurchase authorization of up to $500 million.
Additionally, Prof. Dr. Elaine Mardis stepped down from the Supervisory Board after deciding not to stand for re-election. Prof. Dr. Mardis brought important scientific expertise to the Board since 2014, especially through her service on the Science &amp; Technology and Human Resources &amp; Compensation Committees.
Following the AGM, QIAGEN's Supervisory Board now consists of eight members, reflecting the implementation of a plan announced in 2024 to return to a size consistent with historical levels and continuing to represent all the necessary expertise to support the future development of QIAGEN in a highly effective manner.
The AGM approved the re-appointment for one-year terms of the following Board members: Dr. Metin Colpan, Dr. Toralf Haag, Prof. Dr. Ross L. Levine, Mr. Bert van Meurs, Ms. Eva van Pelt, Dr. Eva Pisa, Ms. Elizabeth Tallett and Mr. Stephen H. Rusckowski.
Shareholders also approved the initiation of QIAGEN's first-ever annual cash dividend - a milestone that reflects QIAGEN's strong financial position and disciplined capital allocation strategy, which includes dividends in addition to organic investments, value-creating acquisitions and share repurchases.
The first dividend payment will be $0.25 per ordinary share, totaling approximately $54 million, with a record and ex-date of July 2, 2025, and payment date of July 10, 2025.
In addition, the AGM approved a new synthetic share repurchase authorization of up to $500 million, reinforcing QIAGEN's commitment to returning capital to shareholders while preserving financial flexibility to invest in innovation and long-term growth.

Dividends

Buybacks

Management

QGEN

QIAGEN Elects Stephen Rusckowski As Chairman Of Supervisory Board; Shareholders Approve Annual Cash Dividend Of $0.25/Shr And Synthetic Share Repurchase Authorization Of Up To $500M

A new film about Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is in the works. Here's why Meta CEO<a href="https://www.benzinga.com/topic/mark-zuckerberg"> Mark Zuckerberg</a> might not be happy about seeing his company on the big screen.
What Happened: A sequel to the 2010 film "The Social Network," which Zuckerberg <a href="https://www.benzinga.com/news/21/10/23381351/5-things-you-might-not-know-about-facebooks-mark-zuckerberg-2">was highly critical of</a>, is in the works.
Tentatively titled "The Social Network Part II," the film comes from the Sony Group Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) unit of Sony Pictures, according to a report from <a href="https://deadline.com/2025/06/the-social-network-sequel-aaron-sorkin-1236439539/">Deadline</a>. According to the report, the film will not be a straight sequel, but rather a follow-up to the first film.
Aaron Sorkin, who wrote the screenplay for the first film, is returning to write the screenplay and direct the film. David Fincher, who directed the first film, is not mentioned in the report on the sequel.
While the first film was based on the book "The Accidental Millionaires" by Ben Mezrich, the new movie will focus on the story "The Facebook Files" from the Wall Street Journal. That story exposed the inner workings of Facebook and the potential harm it has done.
Sorkin has been vocal about wanting to do a follow-up to the hit 2010 movie; now it appears he&#8217;s found his angle with "The Facebook Files."
The writer and director also said in an interview last year that he believes Facebook played a role in the Jan. 6 attack on the U.S. Capitol. The new film won't focus solely on Jan. 6 or the 2020 election. It will also examine the potential harmful impact of Facebook on teenagers and preteens.
Todd Black, Peter Rice, Stuart Besser and Sorkin will produce the film. A production date has not been announced, with Sorkin likely working on casting first.
It is unknown if Jesse Eisenberg, who played Zuckerberg in the 2010 film, will return for the follow-up movie.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: The 2010 film focused on the early days of Facebook&#8217;s creation. It examined several disputes, including those between Zuckerberg and key figures in the company&#8217;s early days, such as the Winklevoss twins and Eduardo Saverin.
Zuckerberg has criticized that film on several occasions, saying it had many inaccuracies.
"It's interesting what stuff they focused on getting right; like, every single shirt and fleece that I had in that movie is actually a shirt or fleece that I own. So there's all this stuff that they got wrong and a bunch of random details that they got right," Zuckerberg said.
Zuckerberg may be even more concerned about the second movie as it will center on a report that sheds a negative light on the social media company.
"The Social Network" grossed $97 million domestically and $225 million globally, according to BoxOfficeMojo.
The film won three Academy Awards for Best Adapted Screenplay, Best Film Editing and Best Original Score. The film was nominated for eight Academy Awards, including top categories like Best Picture, Best Director and Best Actor for Eisenberg.
Meta Platforms&#8217; stock is up 233% over the last five years. Shareholders will closely watch the timing of the movie release to see if the film could harm the company's brand and share price.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/04/44854679/time-100-most-influential-people-includes-elon-musk-mark-zuckerberg-alex-karp-and-more-public-company-ceos">Time 100 Most Influential People Includes Elon Musk, Mark Zuckerberg, Alex Karp And More Public Company CEOs</a></li>
</ul>
Photo: Shutterstock

Entertainment

Sony Group Corporation American Depositary Shares

SONY

Mark Zuckerberg Hated 'The Social Network' Film: Don't Tell Him A Sequel Is Coming

Stifel analyst Brian Chin maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and raises the price target from $130 to $145.

Stifel Maintains Buy on Micron Technology, Raises Price Target to $145

<a href="https://www.youtube.com/watch?v=vIRh3tzaJ48" title="https://www.youtube.com/watch?v=vIRh3tzaJ48">https://www.youtube.com/watch?v=vIRh3tzaJ48</a>

Macro Economic Events

Politics

Global

Economics

White House Says No Indication That Any Enriched Uranium Was Removed From Any Sites In Iran

Stifel analyst Matthew Smith maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Buy and lowers the price target from $65 to $56.

Stifel Maintains Buy on General Mills, Lowers Price Target to $56

Stifel analyst Erik Rasmussen maintains Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) with a Buy and lowers the price target from $1050 to $1010.

EQIX

Stifel Maintains Buy on Equinix, Lowers Price Target to $1010

Stifel analyst Brad Reback maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Hold and raises the price target from $120 to $135.

DDOG

Stifel Maintains Hold on Datadog, Raises Price Target to $135

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang has admitted that he <a href="https://www.benzinga.com/general/education/25/05/45504571/does-jensen-huang-check-nvidia-stock-price-daily-2">doesn't check the price</a> of his company's stock every day. He might want to look at the stock now, as it has recently hit new all-time highs.
Here's a look back at how much Huang and other investors who bought or owned shares when the company went public have made.
Investing $1,000 in Nvidia at IPO: Nvidia became one of the&nbsp;<a href="https://www.benzinga.com/news/23/05/32630114/nvidia-becomes-ninth-company-to-hit-1-trillion-market-cap-who-could-be-next-to-join-elusive-club" target="_blank" rel="noreferrer noopener">most valuable companies</a>&nbsp;in the world in May 2023, passing the $1 trillion market capitalization level.
Since that time, the company went on to pass the $2 trillion and $3 trillion market capitalization levels. At the time of writing, Nvidia is the&nbsp;<a href="https://www.benzinga.com/markets/tech/25/06/45763363/nvidia-overtakes-microsoft-as-the-worlds-most-valuable-company-with-3-4-trillion-market-cap-as-morgan-stanley-reaffirms-top-pick-status" target="_blank" rel="noreferrer noopener">most valuable company</a>&nbsp;in the world valued at $3.79 trillion, slightly ahead of Microsoft Corporation ($3.68 trillion).
Back in 1999, Nvidia held its initial price offering on Jan. 22, with shares priced at $12 each.
A $1,000 investment in the company would have allowed for the purchase of 83.33 shares at the time.
Since its IPO, Nvidia has undergone several stock splits, which have increased the number of shares held by shareholders. The stock had 2:1 splits in 2000, 2001, and 2006, a 3:2 split in 2007, a 4:1 split in July 2021, and the most recent 10:1 split in June 2024.
Today, the original 83.33 shares would total 39,998.4 shares after the stock splits.
The original $1,000 investment in Nvidia stock would be worth $6,214,951.39 based on a share price of $155.38. This represents a huge return for Nvidia IPO buyers with some potential millionaires created over the years.
For comparison, the same $1,000 invested in the&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, would have underperformed Nvidia.
A $1,000 investment in SPY stock could have bought 12.82 shares at the time, based on an adjusted price of $78.03 on Jan. 22, 1999.
The $1,000 invested in the SPDR S&amp;P 500 ETF Trust would be worth $7,831.99 today.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
What Happened:&nbsp;Nvidia has been at the forefront of the AI revolution and growth as a leader in the sector, which helped boost the stock price over the last several years.
Since its was&nbsp;<a href="https://www.nvidia.com/en-us/about-nvidia/corporate-timeline/" target="_blank" rel="noreferrer noopener">founded&nbsp;</a>in 1993, Nvidia has sought to be at the forefront of technological advancements to help new industrial advancements.
In 1999, the company invented the Graphics Processing Unit, commonly known as GPU today. The GPU redefined the computer industry.
In 2012, Nvidia ushered in the modern era of AI with the AlexNet neural network, potentially showing the company ahead of others when it came to belief in the capabilities of artificial intelligence.
In March 2024. the company&nbsp;<a href="https://www.benzinga.com/news/24/03/37809836/nvidia-reveals-blackwell-gpu-highlights-partnerships-with-top-companies-at-gtc-the-whole-industry-is" target="_blank" rel="noreferrer noopener">unveiled the&nbsp;Blackwell GPU</a>,&nbsp;which could help the company further disrupt the growth of artificial intelligence.
What&#8217;s Next:&nbsp;Nvidia continues to&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45675006/nvidia-stock-has-significant-upside-as-ai-godfather-jensen-huang-delivers-another-robust-quarter" target="_blank" rel="noreferrer noopener">draw praise from analysts</a>&nbsp;as one of the best plays on the growth of artificial intelligence.
The big question for investors today is if Nvidia will keep outperforming the overall market and be one of the top-performing stocks going forward.
Nvidia&nbsp;<a href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong" target="_blank" rel="noreferrer noopener">beat analyst estimates</a>&nbsp;in the first quarter for both revenue and earnings per share. Nvidia CEO&nbsp;Jensen Huang&nbsp;highlighted the continued growth of AI and the company&#8217;s new products seeing huge demand, which came despite restrictions on exports to China.
Huang added that demand for Nvidia&#8217;s AI infrastructure is &#8220;incredibly strong.&#8221;
"Countries around the world are recognizing AI as essential infrastructure — just like electricity and the internet — and NVIDIA stands at the center of this profound transformation," Huang said.
The future looks bright for Nvidia and time will tell if investors today can turn their thousands into millions of dollars in the future.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46117402/jensen-huang-closes-in-on-top-10-richest-list-with-nvidia-stock-at-new-highs-heres-how-much-he-needs">Jensen Huang Closes In On Top 10 Richest List With Nvidia Stock At New Highs: Here&#8217;s How Much He Needs</a></li>
</ul>
This article was previously published by Benzinga and has been updated.

Education

NVDA

If You Invested $1,000 In Nvidia Stock At IPO, Here's How Much You'd Have Now

Stifel analyst J. Bruce Chan upgrades Forward Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) from Hold to Buy and raises the price target from $21 to $29.

Upgrades

FWRD

Stifel Upgrades Forward Air to Buy, Raises Price Target to $29

Republic, a New York-based investment platform, has started offering <a href="https://www.benzinga.com/news/space/25/06/46012079/elon-musks-spacex-suffers-major-setback-as-starship-rocket-explodes-in-static-fire-test">tokenized exposure to SpaceX shares</a>, aiming to give retail investors access to private company stakes that were traditionally limited to large, accredited investors.
What Happened: The company's digital tokens, which do not confer direct ownership but provide exposure to share performance, will soon be available for purchase, with plans to expand the offering to other private giants like OpenAI, Anthropic, Stripe, X, Waymo, and Epic Games, <a href="https://www.wsj.com/finance/investing/republic-investing-tokens-companies-ipo-ccff7f91?mod=hp_lead_pos5">according</a> to The Wall Street Journal.
Republic co-CEO Andrew Durgee <a href="https://www.cnbc.com/2025/06/25/blockchain-investing-startup-republic-to-allow-users-to-buy-tokenized-spacex-shares.html">told</a> CNBC the initiative is designed to open doors for retail investors who have long been excluded from pre-IPO opportunities.
&#8220;The fact that retail investors couldn't own pre-IPO SpaceX has always been crazy to us," Durgee said, emphasizing the company's focus on assets with broad public interest.
Tokenization in crypto involves creating blockchain-based representations of assets like stocks or commodities. Investors in these tokenized products gain price exposure but do not hold the actual underlying assets.
The announcement comes as the U.S. crypto industry enters a more permissive regulatory climate under President Donald Trump's administration. 
Recent regulatory developments include the SEC dropping enforcement cases against Coinbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and other major crypto players, scaling back crypto enforcement units, and clarifying that meme coins are not securities. 
A new Crypto Task Force is also actively engaging with the industry through policy roundtables.
Durgee noted that the crypto space, once mired in restrictive oversight, is now benefiting from a more supportive environment. 
"We've moved from nothing but headwinds to having industrywide tailwinds," he said.
Republic will allow retail investors to purchase tokenized shares with investments ranging from $50 to $5,000, significantly lowering the usual barriers to entry. 
Private company shares are typically accessible to accredited investors with higher minimum investment thresholds.
The tokens will initially be priced based on secondary market valuations of SpaceX shares. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46116462/prediction-market-kalshi-raises-185m-surges-to-2b-valuation">Prediction Market Kalshi Raises $185M, Surges To $2B Valuation</a>
Why It Matters: The offering raises fresh regulatory questions, including how tokenized private equity aligns with disclosure rules, whether such structures could increase risks to retail investors, and how companies being represented will respond to this method of investment access.
Durgee said companies' approval isn't required for these offerings under the current securities framework, which was built on laws dating back to the 1930s. 
"People will really have to start questioning how they approach these innovations and how far they want to push the risk envelope," he added.
The push toward tokenization is gaining broader institutional interest. Proponents cite benefits like faster settlements, reduced transaction costs, increased transparency, and improved global accessibility for retail participants. 
Coinbase recently announced its intent to seek SEC approval to list tokenized public stocks, potentially expanding its offerings to compete directly with trading platforms like Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) and eToro. 
Kraken has also signaled plans to offer 24/7 tokenized stock trading in international markets.
BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) CEO Larry Fink has called the tokenization of financial assets a critical step in transforming financial markets.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46114220/asias-microstrategy-metaplanet-acquires-additional-1234-bitcoin-as-etfs-extend-12-day-inflow-streak">&#8216;Asia&#8217;s MicroStrategy&#8217; Metaplanet Acquires Additional 1,234 Bitcoin As ETFs Extend 12-Day Inflow Streak</a></li>
</ul>
Image: Shutterstock

COIN

HOOD

Retail Investors Can Now Trade SpaceX Shares: Here's How

WIIM

NA stock has given up its prior loss. Nano Labs shares were trading lower after the company announced a $50 million offering of Class A ordinary stock and warrants.

Press Releases

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

Legal

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

Small Cap

Opinion

AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

Smart Healthcare Is Taking Over. Here's Where the Money's Headed

AMZN

AVAI

CCLD

CCLDO

CERT

GOOG

GOOGL

MSFT

OMDA

POAI

RENB

TREN

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

CervoMed

Cue Biopharma

Elutia

Forte Biosciences

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

ImmuCell

IGM Biosciences

Immix Biopharma

Immunic

Opus Genetics

Metagenomi

MediciNova

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PMV Pharma

Renovaro

Repare Therapeutics

Serina Therapeutics

Sutro Biopharma

Vor Biopharma

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Screenshot 2024-05-06 at 6.05.33 PM

Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection

Comments

Renovaro

Noticias

Últimas noticias sobre Renovaro (NASDAQ:RENB) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL